However, it is thought to be due to imprecise intra-arterial injection leading to arterial thrombosis and subsequently leading to pain, vasospasm, embolism, sympathetic nerve stimulation leading to necrosis in cutaneous, subcutaneous, adipose, and/or muscle tissues.[ , ] Diagnosis is mostly clinical
Dosing Schedules from Published Research Phase 2 Trial Dose Groups The Phase 2 clinical trial published in NEJM employed the following dose groups, all administered via subcutaneous injection once weekly: Scroll sideways to view the full table on mobile
Excessive release of zonulin results in weakening of TJ and consequent passage of antigens into the vicinity of immune cells and into the circulatory system
While technically possible for a single-use application, it's a risky approach for a blend you'll be using over several weeks
Carla would be happy to help you get set up with self-administered shots at home